Search Results
Jan 07, 2026, 09:07 ET KilgourMD Announces Exclusive Partnership With N1 Life to Bring Peptide-Based Delivery Technology to Scalp Health
applies these technologies to a diverse R&D program, spanning oncology to dermatology diseases, using payloads ranging from small molecules to RNA/DNA. Their mission is to enhance targeted drug delivery, ensuring that treatments reach their intended cells and tissues effectively, thus opening new
More news about: KilgourMD
Jan 07, 2026, 09:00 ET OLAY Debuts New Regenerist Micro-Sculpting Cream with Triple Collagen Peptide, Joined by Ambassador Sarah Michelle Gellar
ensuring its formulas deliver accessible, high-performance results for every skin type and tone.This commitment has long been part of OLAY's DNA: when women feel confident in their skin, they can face anything.The new OLAY Regenerist Micro-Sculpting Cream is available at OLAY.com
More news about: OLAY
Jan 07, 2026, 08:50 ET ProRx Pharma Redefines NAD+ Delivery with New Oral System for Medical Clinics
NAD+ formulation. This advancement introduces a new, convenient option for medical clinics and wellness providers seeking to support cellular energy, DNA repair, and long-term vitality in their patients without relying on daily injectable protocols.
More news about: ProRx Pharma
Jan 07, 2026, 07:52 ET TCL Unveils Breakthrough SQD-Mini LED Display Technology and AI-Driven Smart Living Innovations at CES 2026
sustainability and artistic accessibility.Demonstrating a long-term commitment to the planet, the TCLGreen initiative is embedded in the company's DNA, aiming to inspire greatness by creating a greener world for all while enhancing personal wellbeing. A standout achievement of this initiative is the
More news about: TCL
Jan 07, 2026, 07:33 ET TCL Unveils Breakthrough SQD-Mini LED Display Technology and AI-Driven Smart Living Innovations at CES 2026
sustainability and artistic accessibility.Demonstrating a long-term commitment to the planet, the TCLGreen initiative is embedded in the company's DNA, aiming to inspire greatness by creating a greener world for all while enhancing personal wellbeing. A standout achievement of this initiative is the
More news about: TCL
Jan 07, 2026, 00:21 ET Nebula Next Debuts at CES 2026, Accelerating Globalization Strategy
and product innovation experience in the intelligent hardware sector. This forms an organizational structure driven by a "Smart + Manufacturing" dual DNA.
More news about: Nebula Next
Jan 06, 2026, 16:37 ET Noninvasive prenatal screening could prevent permanent hearing loss in newborns
viruses and bacteria for free-floating fragments of DNA (called cell-free DNA) from CMV.They found CMV DNA in 2.1% (462) of the pregnancies studied. The researchers divided those patients' blood samples into four groups based on the amount of viral DNA detected, ranging from least to most. They validated
More news about: Association for Diagnostics & Laboratory Medicine (ADLM)
Jan 06, 2026, 16:04 ET Advances in maternal-fetal and neonatal diagnostics highlighted in special January issue of ADLM's Clinical Chemistry journal
leading cause of congenital hearing loss. In the realm of molecular diagnostics, new research highlights developments made by sequencing the DNA of pediatric cancer patients and links specific sequences to tumor risk. A perspective article describes how CRISPR, a groundbreaking gene-editing technique,
More news about: Association for Diagnostics & Laboratory Medicine (ADLM)
Jan 06, 2026, 10:15 ET Wendy Buckley Joins PROACTIVE Real Estate Brokerage
perspective support the firm's focus on helping clients build long-term value and generational wealth through real estate.With her strong "hospitality DNA" and results-oriented mindset, Wendy Buckley strengthens PROACTIVE Real Estate's commitment to exceptional service, trusted expertise, and elevated client
More news about: PROACTIVE Real Estate
Jan 06, 2026, 10:01 ET Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
-- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January
More news about: Quest Diagnostics
Jan 06, 2026, 09:15 ET Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jan 06, 2026, 09:00 ET BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
patient reluctance to undergo invasive procedures. To overcome these barriers, the investigators adopted plasma-based liquid biopsy using cell-free DNA (cfDNA) genomic analysis as a non-invasive alternative to tissue-based genomic testing.With sensitivity as a critical performance metric, investigators
More news about: BillionToOne
Jan 06, 2026, 08:00 ET Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding
Together, the companies aim to provide cell-type selective, durable DNA-based gene expression cargo with safe and effective, intracellular fusion-based delivery. The combined innovative technology could be applied to treat
More news about: CHROMATIN BIOSCIENCE LTD
Jan 06, 2026, 08:00 ET Freenome Delivers Improved Performance in Its Colorectal Cancer Blood Test with Sensitivity of 85% for CRC and 22% for Advanced Precancerous Lesions
SimpleScreen CRC was built using this platform and applies an AI/ML-based model to detect specific methylation signatures in tumor-derived cell-free DNA (cfDNA) at single-base resolution.Freenome has also been working on upgrades to the AI/ML learning algorithm; these improvements will be described
More news about: Freenome Holdings, Inc.
Jan 06, 2026, 07:37 ET EdgeLabs Officially Enters the European Market Through Strategic Partnership with SpinOro
"We're thrilled to take our relationship with SpinOro to the next level. At our core, both companies are builders of great games; that shared DNA makes this partnership incredibly natural and exciting. Together we'll bring best-in-class content, enhanced promotional tools, custom game development,
More news about: EdgeLabs
Jan 06, 2026, 03:30 ET LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Disease
HD. DNA mismatch repair has been shown as a key driver of HD and other triplet repeat diseases. Convergent evidence from human genetics, post-mortem studies, and mechanistic research identifies MSH3/MutSβ as the most promising target of the DNA mismatch repair pathway. However,
More news about: LoQus23 Therapeutics
Jan 05, 2026, 11:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
Kong, China, GenEditBio is a clinical-stage gene therapy startup with a strategic goal of providing in vivo genome-editing therapeutic solutions (dubbed "DNA surgery") that are fundamentally safe, precise, efficacious, and affordable for genetic diseases with unmet needs. The Company's core areas of focus
More news about: GenEditBio Limited
Jan 05, 2026, 09:00 ET Eliza and Kickdrum Join Forces to Launch OpenAI Technical Training Academy
team for nearly five years, this was the perfect opportunity to combine our strengths and bring a true partnership to life," said Kennedy. "Kickdrum's DNA is rooted in solving complex software challenges while deliberately investing in the next generation of technologists. Together, we are creating a program
More news about: Eliza
Jan 05, 2026, 09:00 ET Rare Beauty by Selena Gomez to Launch Nationwide in Ulta Beauty
and Chief Executive Officer, Ulta Beauty. "Supporting and giving back to our community through the Ulta Beauty Charitable Foundation is core to our DNA and reaffirms our commitment to using beauty as a force for good. To team up with Selena and Rare to authentically deliver on our values and drive impact
More news about: Rare Beauty
Jan 05, 2026, 08:01 ET MONSTER ENERGY INTRODUCES MONSTER ENERGY STRAWBERRY SHOT
bold and refreshing new way to enjoy the legendary OG Monster flavor, now with an added shot of strawberry that pumps up the taste without changing the DNA fans know and love.
More news about: Monster Energy
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Kelun-Biotech
Jan 05, 2026, 03:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
Kong, China, GenEditBio is a clinical-stage gene therapy startup with a strategic goal of providing in vivo genome-editing therapeutic solutions (dubbed "DNA surgery") that are fundamentally safe, precise, efficacious, and affordable for genetic diseases with unmet needs. For more information, please visit
More news about: GenEditBio Limited
Jan 04, 2026, 23:02 ET 引正基因首個體內基因組編輯藥物GEB-101獲得FDA新藥臨床試驗批准 用於治療TGFBI相關眼角膜營養不良
基因中的特定位置，並由公司自主開發的工程化蛋白遞送載體（PDV）實現精準體內遞送。GEB-101正在研究者發起的臨床試驗中進行安全性和初步有效性評估。關於引正基因GenEditBio引正基因成立於 2021 年，總部位於中國香港，是一家臨床階段的基因治療初創公司，致力於提供安全、精準、有效和可負擔的體內基因組編輯治療解決方案（簡稱「DNA 手術」），以填補臨床醫治未能滿足的需求。公司的核心研發領域包括新型 Cas 核酸酶基因組編輯器的開發，以及利用脂質納米顆粒（LNP）與工程化蛋白遞送載體（PDV）實現安全和高效的體內遞送。公司在香港、北京和波士頓設有研究實驗室和辦公室。引正基因由頂級生命科學投資者資助，包括啟明創投、方圓資本、晟德藥業、順天醫藥、香港科技園創投基金等。如要更多資訊，請到訪公司網頁
More news about: GenEditBio Limited
Jan 04, 2026, 09:00 ET Zeroth Robotics Launches into the U.S. with Debut Lineup of Interactive AI Robots for Consumer and Commercial Buyers
execution, combining autonomous mobility with remote operation. Zeroth's Technology DNABeyond its first product, M1, Zeroth is building a multi-robot future on what it calls its Technology DNA – a unified stack that will power all forthcoming consumer and commercial robots. This foundation
More news about: Zeroth
Dec 31, 2025, 07:25 ET Smart Oncology: 5 Stocks Chasing the $317B Prize
tumors."The NeXT Personal test tracks up to 1,800 tumor-specific variants unique to each patient, achieving ultrasensitive detection of circulating tumor DNA. Patients with decreasing ctDNA levels early in treatment had significantly higher overall survival, while those with increasing ctDNA had a zero percent
More news about: USA News Group